Novel delivery systems for the development of tuberculosis vaccines

Unfortunately, this opportunity is currently unavailable. Please check back at a later date.


This project aims to develop new generation vaccines to combat tuberculosis.


Dr Jamie Triccas, Professor Warwick J Britton

Research Location

Camperdown - Central Clinical School

Program Type



Tuberculosis (TB) is one of the most important causes of disease and untimely death globally. A third of the world's population is infected with Mycobacterium tuberculosis and annually there are 9 million new cases of clinical TB and 1.5 million deaths, the majority occurring in South-East Asia.

The current vaccine, Mycobacterium bovis bacille Calmette-Guerin (BCG), is only partially effective against disease and has had little impact on TB control. Thus there is a clear and urgent need to develop more effective vaccines to control TB in humans.

This project will determine if novel adjuvant designed to target important immune cells (e.g. dendritic cells (DCs) can be used for the effective delivery of novel TB vaccines. We will use existing subunit vaccines that include antigens discovered in our laboratory (see Pinto et al, JID, 2013, 207:778) and within the project we will also develop new generation fusion protein vaccines. Vaccines will be assessed for their ability to target DCs, stimulate effective immune responses and protect mice against infection with virulent M. tuberculosis. The most effective candidates will be prepared for Phase I testing in humans.

Additional Information

Techniques and resources: Culture of pathogenic bacteria (PC3 laboratory); Recombinant DNA technology; animal handling; vaccination strategies; various immunological techniques (cell isolation, ELISPOT, multi-parameter flow cytometry).

Want to find out more?

Contact us to find out what’s involved in applying for a PhD. Domestic students and International students

Browse for other opportunities within the Camperdown - Central Clinical School .


tuberculosis, immune response, Vaccines, Adjuvant

Opportunity ID

The opportunity ID for this research opportunity is: 1201

Other opportunities with Dr Jamie Triccas

Other opportunities with Professor Warwick J Britton